Cosmos Health Inc. - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES

Ticker Exchange SIC # Website Latest Ticker
COSM Nasdaq 5122 www.cosmoshealthinc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cosmos Health Inc.

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million - Oct 7th, 2026 7:30 am
COSM Continues to Surge Revenue Growth - Oct 7th, 2026 7:14 am
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion - Oct 1st, 2026 1:58 pm
COSM Continues to Grow Business - Sep 29th, 2026 11:03 am
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue - Sep 29th, 2026 7:30 am
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline - Sep 28th, 2026 6:00 am
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June - Sep 15th, 2026 8:30 am
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market - Sep 14th, 2026 1:59 pm
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units - Sep 11th, 2026 9:10 am
COSM Again Expands its Market and Accelerates its Growth - Sep 10th, 2026 6:11 am
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market - Sep 9th, 2026 7:30 am
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions - Aug 28th, 2026 7:30 am
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories - Aug 24th, 2026 1:40 pm
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term - Aug 20th, 2026 7:30 am
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway - Aug 19th, 2026 7:00 am
COSM Produces Stellar Quarter - Aug 19th, 2026 5:44 am
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels - Jul 27th, 2026 11:05 am
COSM Marking Huge Growth and Buying Back Shares - Jul 24th, 2026 5:06 am
Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units - Jul 20th, 2026 1:46 pm
Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases - Jul 17th, 2026 12:55 pm